WebFeb 27, 2024 · As explained in this Federal Register Notice, the Cancer Moonshot Expedited Examination Pilot Program began on February 1, 2024 and replaced the Cancer Immunotherapy Pilot Program, which expired ... WebMarch 28, 2024, no applications have been granted special status under this program. This new initiative joins other expedited examination programs instituted by the USPTO, including programs supporting COVID, cancer immunotherapy, and climate change mitigation. The new pilot program requires participants to be reasonably

The Cancer Immunotherapy Pilot Program: An Update

WebAccording to the USPTO, it receives approximately 900 cancer immunotherapy-related applications annually. 4 The Cancer Immunotherapy Pilot Program is open to any applicant, including universities, early stage biotech companies, and large pharmaceutical companies. 5 There are also no eligibility restrictions based on where the technology was ... WebBiotech/Pharma Patent Attorney & Partner at Morgan, Lewis & Bockius LLP Report this post Report Report shucks on durango

Cancer Moonshot Expedited Examination Pilot Program

WebSep 15, 2024 · The Cancer Immunotherapy Pilot Program offers expedited examination of patent applications related to cancer immunotherapy, with a final decision issued within one year. The USPTO participates in Patent Prosecution Highway (PPH) programs (e.g., Global Patent Prosecution Highway (GPPH) or IP5 PPH) for either a U.S. direct … WebJul 13, 2024 · USPTO Announced Further Extending the Fast-Track Program for Cancer Products: The USPTO announced a further extension of its Patents for Patients or … WebJul 12, 2016 · The Cancer Immunotherapy Pilot Program will run 12 months until June 29, 2024. Applicants who are interested in participating in the program should file a petition to make special under the Cancer Immunotherapy Pilot Program. Requirements for participating in the program are as follows: Type of Application. The application must be … the other guys common sense media